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Abstract: Transglutaminase 2 (TG2) is the most widely distributed and most abundantly 
expressed member of the transglutaminase family of enzymes, a group of intracellular and 
extracellular proteins that catalyze the Ca
2+
-dependent post-translational modification of 
proteins. It is a unique member of the transglutaminase family owing to its specialized 
biochemical, structural and functional elements, ubiquitous tissue distribution and sub-
cellular localization, and substrate specificity. The broad substrate-specificity of TG2 and its 
flexible interaction with numerous other gene products may account for its multiple 
biological functions. In addition to the classic Ca
2+
-dependent transamidation of proteins, 
which is a hallmark of transglutaminase enzymes, additional Ca
2+
-independent enzymatic and 
non-enzymatic activities of TG2 have been identified. Many such activities have been 
directly or indirectly implicated in diverse cellular physiological events, including cell growth 
and differentiation, cell adhesion and morphology, extracellular matrix stabilization, wound 
healing, cellular development, receptor-mediated endocytosis, apoptosis, and disease 
pathology. Given the wide range of activities of the transglutaminase gene family it has been 
suggested that, in the absence of active versions of TG2, its function could be compensated 
for by other members of the transglutaminase family. It is in the light of this assertion that we 
review herein, TG2 activities and the possibilities and premises for compensation for its 
absence.  
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1.0: Introduction 
The human transglutaminase 2 (TGM2) gene localizes to chromosome 20q11-12 and its 
exons span approximately 37 kb (Gentile et al. 1994). The protein, transglutaminase 2 (TG2, 
EC 2.3.2.13) is made up of 687 amino acids, with molecular mass of 77.3 kDa (Fraij & 
Gozales, 1997; Fesus & Piacentini, 2002). Transglutaminase 2 (TG2) is also known as tissue 
transglutaminase (tTG), cytosolic, type II, or liver transglutaminase. It is the most abundant 
and most studied of the nine members of the transglutaminase enzyme family, including 
TG1, TG3 and TG5 isoforms, which are predominantly expressed in epithelial tissue; TG4, 
which is expressed in the prostate gland; factor XIII (FXIII), which is expressed in the blood; 
TG6 which is expressed in the testis, lungs, and brain (Mehta, 2005; Thomas et al. 2013) ; 
TG7, which is ubiquitously expressed, but most prominently distributed in the testis and 
lungs (Mehta, 2005). 
 
A further member of the TG2 family is band 4.2, which is an enzymatically inactive protein 
component of the erythrocyte membrane that shares homology with many transglutaminases 
but lost the characteristic transglutaminase activity as a result of an amino acid substitution 
(Cys-Ala) at the active site (Lorand & Graham, 2003; Mehta 2005). It is expressed in the 
surface of erythrocyte membranes, bone marrow, foetal liver, spleen and serves as a key 
component of erythrocyte skeletal network, where it maintains erythrocyte shape and 
mechanical properties (Lorand & Graham, 2003; Mehta, 2005) (table 1).  
 
 
Furthermore, shorter forms of TG2 with different properties have been reported to be 
produced through the alternative splicing of transglutaminase 2 encoding gene (TGM2) (Fraij 
et al. 1992; Fraij, 1996; Fraij & Gonzales, 1996, 1997). A total of four spliced forms of TG2 
have been reported, including TG2-S, TG2-H2, TG2v1 and TG2 v2; but their roles in vivo are 
yet to be defined (as reviewed by Lai and Greenberg, 2013). The major difference between 
TG2 and its spliced isoforms is that all the spliced isoforms lose their C-terminus to different 
extents; therefore, they cannot undertake the characteristic functions of TG2 like GTP/ATP 
binding, PLC binding,  migration and adhesion functions, etc. (Im et al. 1997; Murthy et al. 
1999; Lai et al. 2007). Though, some of these isoforms of TG2 are yet to be properly 
characterised, TG2 short isoform (TG2-S), which lacks the C-terminal 138 amino acid 
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residues of full length TG2, has been characterised and reported to be up-regulated in brain 
tissue of Alzheimer’s patients (Citron et al. 2001, 2002; Antonyak et al. 2006). 
 
Table 1: Members of the transglutaminase (TGase) enzyme family, their nomenclature, 
tissue distribution, biological functions, and pathological involvement (Esposito & 
Caputo, 2005; Mehta 2005) 
TGase Nomenclature Tissue 
distribution, 
cellular and sub-
cellular 
localization  
Biological 
Functions 
Pathology 
TG1 Keratinocyte TG, 
particulate TG, 
TG1, TGK 
Squamous epithelia, 
keratinocytes, 
cytosolic, 
membrane 
Barrier function in 
stratified squamous 
epithelia, cornified 
envelope formation 
in keratinocyte 
differentiation  
Lamellar Ichthyosis 
(Candi et al 1998) 
TG2 Liver TG, tissue 
TG, cytosolic TG, 
erythrocyte TG, 
Ghα, endothelial 
TG 
Ubiquitously 
distributed in many 
types of tissue, cell 
membrane, cytosol, 
nucleus, 
extracellular  
Apoptosis, cell 
survival signalling, 
cell differentiation, 
matrix stabilization, 
endocytosis, etc  
Autoimmune 
diseases, 
neurodegenerative 
diseases, 
malignancies, 
metabolic diseases, 
etc (Facchiano & 
Facchiano, 2006) 
TG3 Epidermal TG, 
callus TG, hair 
follicle TG, bovine 
snout TG 
Epidermis, hair 
follicle, brain, 
cytosolic 
Terminal 
differentiation of 
keratinocytes, hair 
follicles  
Human epidermis 
diseases 
TG4 Prostate TG, TGp, 
androgen regulated 
major secretory 
protein, vesiculase, 
dorsal prostate 
protein 1 (DP1), 
type 4 TG 
Prostate gland, 
prostatic fluids, and 
seminal plasma, 
extracellular 
Reproduction and 
fertility, especially 
in rodents where it 
is involved in 
semen coagulation 
Not known  
TG5 TGX, type 5 TG, 
TG5 
Ubiquitously 
expressed but 
predominant in 
female reproductive 
tissues, skeletal 
muscle, and foetal 
tissues, foreskin 
keratinocytes, 
epithelial barrier 
lining, cytosolic 
 
Epidermal 
differentiation 
Secondarily 
involved in 
hyperkeratotic 
phenotype in 
ichthyosis and in 
psoriasis, 
Overexpressed or 
absent in different 
areas of the Darier’s 
disease lesions 
(Candi et al 2002) 
TG6 TGY, type 6 TG, 
TG6,  
Testis, lungs, and 
brain, cellular 
localization is yet to 
be defined 
Central nervous 
system 
development, motor 
function, late stage 
cell envelope 
formation in the 
epidermis 
and the hair follicle 
Spinocerebellar 
ataxias (Wang et al. 
2010; Sailer & 
Houlden, 2012); 
polyglutamine 
(polyQ) diseases 
(Guan et al 2013) 
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TG7 TGZ, type 7 TG, 
TG7, 
transglutaminase 7 
Ubiquitously 
expressed, 
prominent in testis 
and lungs, cellular 
and sub-cellular 
localization are 
unknown  
 Not known 
FXIIIA Factor XIII A, 
fibrin stabilizing 
factor, fibrinoligase, 
plasma TG, 
Laki-Lorand factor 
 
Chondrocytes 
platelets, placenta, 
astrocytes, 
macrophages, 
synovial fluid, 
heart, eye, bone, 
dendritic cells in the 
dermis  
 
Wound healing, 
blood clotting, bone 
growth 
 
F13A1 deficiency 
characterized by 
impaired wound 
healing, 
spontaneous 
abortion in women,  
subcutaneous 
and intramuscular 
haematomas, severe 
bleeding tendency 
Band 4.2 Erythrocyte 
membrane 
protein band 4.2, 
B4.2, ATP-binding 
erythrocyte 
membrane protein 
band 4.2 
Surface of 
erythrocyte 
membranes, bone 
marrow, foetal 
liver, spleen, 
membranal  
Key component of 
erythrocyte skeletal 
network, maintains 
erythrocyte  shape 
and mechanical 
properties 
Spherocytic 
elliptocytosis 
 
 
 
Structurally, TG2 is similar to those of other members of its family, except that it bears some 
specific features which are not characteristic of other type of transglutaminases. Essentially, 
TG2 is composed of four distinct globular domains: A NH2-terminal β-sandwich which 
contains fibronectin and integrin binding sites, a catalytic core which contains the catalytic 
triads (Cys277, His335 and Asp358) for acyl-transfer reaction and a conserved tryptophan 
essential for this catalytic reaction (Murthy et al. 2002; Kiraly et al 2011), and two COOH-
terminal β-barrel domains with the second barrel domain containing a phospholipase C 
binding sequence (Hwang et al. 1995: Liu et al. 2002). 
 
Unlike other transglutaminases, TG2 possesses a unique guanidine nucleotide-binding site, 
located in the cleft between the catalytic core and the first β-barrel (Liu et al. 2002); this 
sequence is coded by exon 10 of the TG2 gene, which is characterised by very poor sequence 
homology with the same exons in other transglutaminases. Some GDP/GTP-interacting 
residues and those necessary for GTP hydrolysis are situated in other domains (Iismaa et al. 
2000). In the GDP-bound form of TG2, access to the transamidation active site is blocked by 
two loops, and the active site cysteine is attached to a tyrosine residue by hydrogen bonding. 
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In the latent conformation of TG2, there is a significant inter-domain interaction between the 
catalytic domain 2 and domains 3 and 4, which reduces the accessibility of the active centre 
(Liu et al. 2002). 
 
Beside the primary transglutaminase enzymes’ activity of catalyzing the calcium-dependent 
posttranslational modification of proteins, TG2 can also bind and hydrolyze GTP (Nakaoka et 
al. 1994), exhibit protein disulphide isomerase activity (Hasegawa et al. 2003), and function 
as a protein kinase independently of calcium (Mishra & Murphy, 2004). Furthermore, TG2 
has calcium-independent non-enzymatic activities, especially extracellularly, where it 
interacts with a number of cell surface proteins (Belkin, 2011), taking part in cell adhesion 
processes and stabilization of the extracellular matrix.  This catalogue of special activities and 
multiple functionalities is underlined by TG2’s structural uniqueness and complexity typified 
by its complex four-domain structure, constituted of an N-terminal β-sandwich, a catalytic 
core, and two C-terminal β-barrel domains (Kiraly et al. 2011). Regardless of the wide range 
of biological functionalities associated with TG2 activities, amidst its unique cellular 
biochemistry, its exact physiological function is still debated. Hence, the view that in the 
event of its absence, the physiological function of TG2 could be compensated for by another 
member(s) of the transglutaminase family. It is against this background, that we considered 
the implications of TG2 expression and TG2-specific activities in biological processes. This 
is done with a view to rationalizing its involvement in many cellular physiological events and 
dissecting the premise that its functional compensation is feasible or unlikely.  
 
2.0: Transglutaminase 2-specific enzymatic activities   
Catalysis of Ca
2+
-dependent post-translational modification of proteins is the major hallmark 
of transglutaminase enzymes. The mechanism of this reaction is generally the same for TG2 
and other members of TG- enzyme family; and involves a two-step process, as recently 
reviewed in Gundemir et al. (2012). The first step is the formation of a thioester bond with 
the enzyme’s active cysteine site via the transamidation of the γ-carboxamide group of a 
peptide bond glutamyl substrate, which is accompanied by the release of ammonia as a by-
product. This is followed by the transfer of the acyl intermediate to a nucleophilic substrate, 
including the ε-amino group of a peptide-bound lysine residue. Consequently, an 
intermolecular isopeptide ε-(γ-glutamyl)lysine bond is formed, which results in the internal 
cross-linking of monomeric protein units (Porta et al. 1991). In transamidation reactions, 
lysine can be replaced by lower molecular mass amines, such as polyamines. Hence, in the 
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presence of high concentration of polyamines, such as spermine, TG2 can form covalent 
cross-linking between two polypeptide chains, in the form of a dimer or an adduct as in the 
case of Gln – Gln or Gln – Gly –  (Porta et al. 1991). These bonds are resistant to chemical 
and physical degradation, hence, they are believed to be of biological significance especially 
in the stabilization of the extracellular matrix (ECM) (Griffin et al. 2002; Belkin, 2011). In 
cellular physiology, the isopeptide bonds formed by TG2 activity have been suggested to be 
functionally important in apoptosis, where they prevent inflammation by ensuring that the 
intracellular contents of dying cells are not released to the extracellular environment 
(Nicholas et al. 2003). However, water can also act as a nucleophile and cause deamidation 
of protein-bound glutamine residues (Porta et al. 1991; Esposito & Caputo, 2005). The 
conversion of the acyl-donor glutamine residue to a glutamate residue triggers deamination. 
Originally, it was believed that the deamination reaction could only take place under 
conditions that do not favour transamidation (Fleckenstein et al. 2002; Gundemir et al. 2012). 
However, studies have reported the tendency of TG2 to carry out specific deamination 
(Stamnaes et al. 2008), when structural features that favour deamination over transamidation 
are present in protein substrates (Pinkas et al. 2007).  
 
 
3.0: Calcium-independent non-enzymatic activities of transglutaminase 2  
 
In addition to the general hallmark of calcium - dependent transamidation activity, TG2 has 
other enzymatic activities, independent of Ca
2+
 as reviewed in Gundemir et al
 
(2012). For 
instance, TG2 can function as a protein kinase (Mishra & Murphy, 2004; Mishra et al. 2006; 
Mishra & Murphy, 2006; Mishra et al. 2007; and Kuo et al 2011); bind and hydrolyze GTP 
(GTPase and G-protein function) (Achyuthan & Greenberg, 1987; Nakaoka et al. 1994; 
Hwang et al. 1995; Chen et al 1996; Feng et al. 1996; Baek et al. 1996; Im et al. 1997; Vezza 
et al. 1999), and exhibit protein disulfide isomerase activity in vitro (Hasegawa et al. 2003) 
and in vivo (Mastroberardino, 2006; Szondy et al. 2006; Malorni et al. 2009); independent of 
calcium as reviewed in Belkin (2011).  
 
Over the past two decades, other functions of TG2 that are independent of its enzymatic 
activities have been established (Akimov et al. 2000; Dardik & Inbal, 2006; Janiak et al. 
2006; Zemskov et al. 2006; Telci et al. 2008; Scarpellini et al. 2009; and Zemskov et al. 
2009). These calcium-independent, non-enzymatic and transamidation-independent activities 
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of TG2 are involved in many critical physiological processes underlying many key aspects of 
cell behaviour, including cell adhesion, growth, migration, differentiation, programmed cell 
death, and ECM assembly (Zemskov et al. 2006).  In turn, these cellular processes are vital to 
embryogenesis and tissue morphogenesis, wound healing and tissue repair, as well as tumor 
growth and metastasis (Hand et al. 2000).  
 
In 1992, Gentile and colleagues first suggested the involvement of transglutaminase 2 in the 
mediation of extra-cellular matrix (ECM) adhesion (Gentile et al. 1992). They observed an 
astonishing effect of TG2 over-expression on the growth of fibroblasts and their increased 
resistance to trypsinization. Subsequent convincing proofs at both the cellular and molecular 
levels, have supported TG2’s involvement in the mediation of cellular interactions with the 
ECM, and have demonstrated that TG2 serves as an adhesion receptor for fibronectin (FN) on 
the cell surface (Verderio et al. 1998; Akimov et al. 2000; Belkin et al. 2001 and Kabir-
Salmani et al. 2005).  
 
Transglutaminase 2 has a very high affinity for FN, to which it has been shown to bind at a 
stoichiometry of 2:1 (LeMosy et al. 1992), independently of either Ca
2+
 or the transamidating 
and GTPase activities of TG2 (Turner et al. 1989). The interaction of TG2 with FN has been 
shown to mediate ECM adhesion (Akimov et al. 2000) and many other adhesion-dependent 
phenomena, such as cell migration, matrix assembly and signalling (Akimov et al. 2001; 
Verderio et al. 2003). The gelatin-binding domain (42kD) serves as the only binding site for 
TG2 on FN, and binds TG2 with similar affinity as the whole FN molecule (Radek et al. 
1993). Additionally, the adhesive function of TG2 is favored by the fact that the 42kD 
gelatin-binding domain of FN has no interaction sites for the numerous FN-binding integrins, 
as well as other FN-associated adhesion receptors (Hang et al. 2005). Therefore, TG2 and 
integrin can independently bind distinct domains of FN, hence supporting a model of 
cooperation rather than engaging in competition in the cell adhesion process (Zemskov et al. 
2006). It has been shown in different cell types that the binding of TG2 to the 42kD fragment 
of FN results in stable cell adhesion, limited spreading and formation of specialized adhesive 
structures at the cell-substrate interface (Belkin et al 2001; Akimov et al. 2001). 
 
Regardless of the co-existence of TG2 and integrin at different FN-binding domains, where 
they are involved in the cell adhesion process, TG2 also associates with integrin to maintain 
cell-extracellular matrix (ECM) interactions. Integrins represent a large class of trans-
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membrane adhesion receptors constituted by distinct non-covalently associated and are 
composed of α and β subunits (Hynes et al. 2002). In all cell types apart from red blood cells, 
24 integrin heterodimers constituted variously of 8 β subunits and 18 α subunits are 
expressed, serving as receptors for a number of ECM ligands and facilitate adhesion between 
cells (Hynes et al. 2002; Humphries et al 2004). The role of integrin in wound healing, blood 
clotting and thrombosis, viral and bacterial infection, inflammation, tumor growth and 
angiogenesis, as well as other pathological and physiological states, exemplifies the 
fundamental functions of integrin in cell-matrix adhesion (Zemskov et al. 2006). 
 
Transglutaminase 2 has been shown to associate with many integrin receptors, by binding to 
the extracellular domains of the β1 and β3 integrin subunits in different cell types (Akimov et 
al. 2000; Belkin et al. 2001; Akimov et al. 2001). The stable, non-covalent TG2-integrin 
complexes are formed independently of the transamidating activity of TG2, and there is no 
evidence of integrin serving as an enzymatic substrate of TG2 or other transglutaminases 
(Akimov et al. 2000). Furthermore, while performing some biochemical experiments on cells 
that do not synthesize FN, Akimov et al (2000), demonstrated that the TG2-integrin 
interaction is not mediated by fibronectin, but is independent. They further observed that 
integrin-TG2 complexes have 1:1 stoichiometry and found that cell-surface TG2 is bound to 
integrin receptors, with the possibility of up to 40% of β1 integrin being associated with TG2 
in various cell types (Akimov et al. 2000; 2001). The ability of TG2 to form ternary adhesive 
complexes with various isoforms of integrin and FN, where all the three proteins successfully 
interact with each other, highlights the importance of TG2 in cell adhesion and indicates an 
unconventional role of TG2 as a co-receptor in cell-matrix interactions (Akimov et al. 2000). 
The implications of these non-enzymatic, calcium- and transamidation-independent activities 
in some key biological events are highlighted below. 
 
4.0: Implications of transglutaminase 2 in biological events: a synoptic update 
Transglutaminase 2 is a multifunctional protein with over 130 substrates at various locations 
inside and outside the cell (Csosz et al. 2009) (table 2). The broad range of specificity of TG2 
for its targets may account for its pleiotropic functionality. However, to achieve a particular 
function necessitates that the selection of a specific subset of protein substrate related to that 
particular biological event must be tightly regulated by additional factors. The various 
physiological implications of TG2 typify the relationships between its diverse biochemical 
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activities and cellular functions, and make it difficult to determine the exact role it plays in 
cell physiology and pathology. 
 
Table 2: Transglutaminase 2 substrates, reactive sites, cellular localizations, and 
possible involvement in human physiology/diseases  
 
TG2 substrate Reactive site Localization Physiology/disease 
Acetylcholine esterase Glutamine  Intracellular  Neurological disease 
(Hand et al. 2000) 
Actin Glutamine and lysine Intracellular  Cytoskeleton regulation 
(Nemes et al. 1997) 
Aldolase Reactive glutamine 
present but specific 
residue is unknown  
Intracellular  Genetic disease, 
endocrine and metabolic 
diseases, autoimmune and 
inflammatory diseases 
(Lee et al. 1992)  
Androgen receptor  Intracellular (nuclear 
receptor) 
Endocrine and metabolic 
diseases (Mandrusiak et 
al. 2003) 
Annexin I (lipocortin I) Glutamine  Intracellular  Autoimmune and 
inflammatory diseases, 
cytoskeleton regulation 
(Ando et al. 1991) 
Calgizzarin - S100C 
protein - MLN 70 – 
S100A11 
Glutamine and lysine Keratinocyte cornified 
envelope  
Endocrine and metabolic 
diseases, dermatological 
diseases (Robinson & 
Eckert, 1998) 
Collagen alpha 1(III) Glutamine  Extracellular  Extracellular matrix 
interaction and 
stabilization, autoimmune 
and inflammatory 
diseases (Orban et al. 
2004)  
α - B-crystallin Lysine Intracellular  Cell life and death, 
cytoskeleton regulation, 
protein stabilization 
(Groenen et al. 1992) 
β - A3 crystallin Glutamine  Intracellular  Cell life and death, 
cytoskeleton regulation, 
protein stabilization 
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(Groenen et al. 1994) 
β -  B3 crystallin Glutamine  Intracellular  Cell life and death, 
cytoskeleton regulation, 
protein stabilization 
(Berbers et al. 1984) 
β -  Bp (betaB2) 
crystalline 
Glutamine  Intracellular  Cell life and death, 
cytoskeleton regulation, 
protein stabilization 
(Berbers et al. 1984) 
Cytocrome c Glutamine  Intracellular  Cell life and death (Butler 
& Landon, 1981) 
Fibronectin Glutamine  Extracellular  Protein stabilization, 
extracellular matrix 
interaction and 
stabilization (Mehta et al. 
2006) 
Fibrinogen A alpha Glutamine and lysine  Extracellular  Extracellular matrix 
interaction and 
stabilization, autoimmune 
and inflammatory 
diseases (Murthy et al. 
2000) 
Glutathione S-transferase Glutamine, lysine, 
fluorescine  
Intracellular  Extracellular matrix 
interaction and 
stabilization (van den 
Akker et al. 2011) 
Gluten proteins Glutamine  Extracellular Celiac disease (Kim et al. 
2002) 
Glyceraldeheyde 3 
phosphate dehydrogenase 
Lysine  Intracellular  Neurological diseases 
(Orru et al. 2002) 
H3 histone Glutamine Intracellular  Cell life and death 
(Ballestar et al. 1996) 
H4 histone Glutamine  Intracellular  Cell life and death 
(Ballestar et al. 1996) 
H2A histone Glutamine  Intracellular  Cell life and death 
(Ballestar et al. 1996) 
H2B histone Glutamine  Intracellular  Cell life and death 
(Ballestar et al. 1996) 
Importin alpha3  Nuclear transport protein  Cell life and death (Kuo 
et al. 2011) 
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α - Ketoglutarate 
dehydrogenase 
Lysine  Intracellular  endocrine and metabolic 
diseases (Cooper et al. 
1997) 
Latent TGF-beta binding 
protein-1 (LTBP-1) 
 Extracellular  Carcinogenesis, 
autoimmune and 
inflammatory diseases 
(Verderio et al. 1999)  
α --2-Macroglobulin 
receptor-associated 
protein 
Glutamine  Extracellular  autoimmune and 
inflammatory diseases 
(Rasmussen et al. 1999) 
Microtubule-associated 
protein tau - isoform Tau-
F (Tau-4) 
Glutamine and lysine  Intracellular  Cytoskeleton regulation, 
neurological diseases 
(Murthy et al. 1998) 
Myosin  Intracellular  Cytoskeleton regulation 
(Eligula et al. 1998) 
Nidogen  Glutamine  Extracellular  Extracellular matrix 
interaction and 
stabilization 
(Aeschlimann et al. 1992) 
Osteocalcin  Extracellular  Autoimmune and 
inflammatory diseases 
(Kaartinen et al 1997) 
Osteonectin Glutamine  Extracellular  Autoimmune and 
inflammatory diseases, 
extracellular matrix 
interaction and 
stabilization 
(Aeschlimann et al 1995) 
Osteopontin Glutamine  Extracellular  Autoimmune and 
inflammatory diseases, 
extracellular matrix 
interaction and 
stabilization (Kaartinen et 
al. 2002) 
Phospholipase A2 Glutamine  Extracellular  Endocrine and metabolic 
diseases, Signal 
transduction, autoimmune 
and inflammatory 
diseases (Cordella-Miele 
et al 1990; Fesus & 
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Piacentini, 2002) 
Troponin T  Intracellular  Cytoskeleton regulation 
(Gorza et al. 1996) 
 
4.1.0: Transglutaminase 2 in cell survival and death processes 
With regards to cell death and survival, the role of TG2 is extremely complex, and for almost 
three decades it has remained under investigation, following the first report of TG2’s 
involvement in apoptosis (Fesus et al. 1987). Transglutaminase 2’s involvement in apoptosis 
could be better described as a double-edged sword as it can be both pro-apoptotic or anti-
apoptotic. Cells undergoing apoptosis show an increased level of TG2 expression, which may 
prime the cell to undergo apoptosis. Its inhibition results in a decreased propensity of cells to 
die by apoptosis (Mehta et al 2006; Verma & Mehta, 2007).  
 
 
4.1.1: Pro-apoptotic activity of TG2 
The pro-apoptotic activity of TG2 is defined by its cross-linking configuration, which 
requires a millimolar concentration of calcium. Stressful conditions, such as ultraviolet 
radiation and chemotherapeutic agents, can generate reactive oxygen species (ROS) - with 
resultant induction of TG2. Further increase in such stressful conditions may further trigger 
the release of Ca
2+
 from the endoplasmic reticulum (ER), resulting in the activation of TG2 
and extensive cross-linking of intracellular proteins, which, in turn, initiates the apoptotic 
process (Mangala & Mehta, 2005; Mehta et al 2006). A major physiological significance of 
TG2 involvement in apoptotic initiation is its mediation of the crosstalk between dying and 
phagocytic cells to ensure tissue and cellular integrity. In essence, the focal function of TG2 
in apoptosis is to ensure that, once the apoptotic process is initiated, it is completed without 
inflammation or tissue injury resulting from the process (Fesus & Szondy, 2005). TG2 can 
achieve maintenance of a cellular environment devoid of inflammation whilst directly 
promoting apoptosis in some cell types (Oliverio et al. 1999) or indirectly promoting the 
activation of TGF-β released by the macrophages, which can promote the death of various 
cells (Szondy et al. 2003; Huang & Lee, 2003), to ensure that all damaged cells are killed 
quickly without the occurrence of necrosis. Additionally, TG2 can promote chemo-attractant 
formation and the release of phosphatidylserine, to, respectively, aid macrophage migration 
to the site of apoptosis and the recognition of apoptotic cells (Nishiura et al. 1998; Fesus & 
Szondy, 2005).  
13 
 
 
4.1.2: Anti-apoptotic activity of TG2 
The anti-apoptotic effect of TG2 is independent of its transamidation and enzymatic cross-
linking activities and does not require calcium. Nuclear TG2 protect cells from death by 
interacting with retinoblastoma protein pRb, polymerizing the alpha-inhibitory sub-unit of the 
transcription factor NF-kappaβ, with the resultant transcriptional regulation of several anti-
apoptotic key genes (Boehm et al 2002). Similarly, TG2 can translocate to the plasma 
membrane where it serves as a co-receptor for integrin, promoting its interaction with 
fibronectin. TG2-mediated interaction between integrin and fibronectin could result in the 
activation of cell survival and anti-apoptotic signalling pathways, and extracellular matrix 
stabilization (Mehta et al. 2006). Also, in the extracellular space, TG2 can stimulate its own 
production by activating latent transforming growth factor beta (TGF-β), which in turn up-
regulates TG2 (Fesus & Szondy, 2005). It is tempting to conclude that the pro-apoptotic and 
anti-apoptotic effects of TG2 are dependent on the activation pathways and localization of the 
protein, with nuclear and extracellular TG2 as anti-apoptotic and cytosolic TG2 is pro-
apoptotic, in agreement with the findings of Milakovic et al (2004). 
 
4.2.0: Transglutaminase 2 in human diseases 
Owing to the pleiotrpic and ubiquitous tissue distribution of TG2, it is not surprising that its 
involvement in many pathological conditions has been variously demonstrated. 
Transglutaminase 2 has been implicated as having a role in various chronic diseases, 
especially in (a) inflammatory diseases, including wound healing, tissue repair and fibrosis, 
and autoimmune diseases; (b) chronic degenerative diseases such as arthritis, atherosclerosis, 
and neurodegenerative conditions like Alzheimer’s and Parkinson’s disease; (c) malignant 
diseases; and (d) metabolic diseases such as diabetes mellitus (Griffin et al. 2002; Facchiano 
et al. 2006).  In most of these diseases, the role of TG2 is mostly related to the dysregulation 
of its functions, especially regarding its interaction with, and stabilization of the cellular 
matrix, rather than its involvement in apoptosis. 
 
4.2.1: Transglutaminase 2 in autoimmune diseases  
In autoimmune diseases such as coeliac disease, the presence of autoantibodies against TG2 
and other substrates is an indication that TG2 may cross-link potential auto-antigens to itself 
and to other protein substrates, triggering an immunological response typical for autoimmune 
diseases (Sollid et al. 1997; Kim et al. 2002). TG2’s role in coeliac disease is related to the 
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deamination of the side chains of glutamine, in the presence of abundant glutamine in gluten 
proteins. This deamination reaction results in an up-regulation of the binding capacity of 
gluten to DQ2 and the response of T-cell clones (Quarsten et al. 1999; Arentz-Hansen et al. 
2000). Additionally, it has been reported that gluten peptides incubated with TG2 create 
covalent complexes through thioester bonds to the active site cysteine of TG2, and via 
isopeptide bonds to particular lysine residues of TG2 (Fleckenstein et al. 2004). Hence, 
gluten proteins and their peptide derivatives serve as substrates for various TG2-catalysed 
reactions (Facchiano et al. 2006). Recently, deamidation of gluten-derived gliadin peptides 
by TG2 was shown to be responsible for gliadin-induced toxicity and immune response in the 
small-intestinal mucosa (Rauhavirta et al. 2013). Consequently, Rauhavirta and colleagues 
suggested that the inhibition of TG2 can reduce gliadin-induced effects (Rauhavirta et al. 
2013). In a different study, Oh et al. (2013) reported that the initiation of allergen response in 
pulmonary epithelial cells requires TG2. 
 
4.2.2: Transglutaminase 2 in inflammatory diseases   
In inflammatory diseases, TG2 plays a pivotal role via its regulatory action on granule 
secretion and macrophage function or by regulating the function of major inflammatory 
mediators like phospholipase A2 (Cordella-Miele et al. 1990). The involvement of TG2 in 
inflammatory diseases and related processes such as angiogenesis and wound healing, has 
been reported (Sohn et al. 2003; Verderio et al. 2005). It is an important effector in the 
pathogenesis of chronic inflammatory diseases, like rheumatoid arthritis and osteoarthritis, by 
converting the latent transforming growth factor binding protein-1 into its active form, TGF-β 
(Nunes et al. 1997). Recently, TG2 has been reported to be directly involved in chronic 
kidney disease (CKD), where it is involved in the pathogenesis of vascular calcification 
through the enhancement of matrix vesicle-ECM interaction (Chen et al. 2013). Similarly, on 
analysis of TG2:creatinine ratio in relation to albumin:creatinine ratio in CKD patients, da 
Silva et al. (2013) suggested that TG2 may be a potential biomarker for CKD detection and 
progression assessment.  
 
4.2.3: Transglutaminase 2 in neurological and metabolic diseases  
In vitro and/or in vivo, many TG2 substrates have been found in neuronal cellular 
compartments: e.g. amyloid beta-A4 peptide, alpha synuclein, the microtubule-associated tau 
protein, synapsin I, and myelin basic protein, as reviewed by Facchiano et al. (2006). TG2-
mediated cross-linking is therefore believed to be implicated in neurodegenerative diseases 
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such as Huntington’s, Alzheimer’s and Parkinson’s diseases (Kim et al. 2002; Bailey et al. 
2005) and in diseases related to neurotransmitter release (Deloye et al. 1997). Similarly, the 
possible involvement of TG2 in neurotransmitter release and related pathological conditions, 
such as that caused by tetanus neurotoxin intoxication, has been reported (Facchiano & Luini, 
1992). 
 
The covalent modification of TG2 substrates such as glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), alpha-ketoglutarate dehydrogenase, phosphoglycerate 
dehydrogenase and fatty acid synthase (Orru et al. 2003), which are involved in energy 
metabolism, could account for the role of TG2 in metabolic diseases. Additionally, TG2-
mediated covalent modification of hormone receptors or hormone-binding proteins indicates 
that TG2-catalysed cross-linking may be involved in controlling complex metabolic 
responses to hormones (Sakai et al. 2001; Mandrusiak et al. 2003). The involvement of TG2 
in the regulation of insulin secretion, and diabetes mellitus has also been suggested (Bungay 
et al. 1984; Bernassola et al. 2002).  
 
4.2.4: Transglutaminase 2 in cancer 
In cancer, transglutaminase 2 has been shown to play a major role in development of drug 
resistance and metastasis in many cancer types, including pancreatic carcinoma (Verma et al 
2006), ovarian carcinoma (Satpathy et al. 2007; Hwang et al. 2008), malignant melanoma 
(Fok et al. 2006), lung carcinoma (Park et al. 2010), glioblastoma (Yuan et al. 2007), and 
breast carcinoma (Mehta et al. 2004). When aberrantly regulated, TG2 could aid tumor cells 
to evade apoptosis and have direct consequences on cancer drug resistance (Mehta, 1994; 
Chen et al. 2002) and metastatic progression (Mehta et al. 2004). For instance, Park et al 
(2009) reported that TG2-specific cross-linking activity resulted in the polymerization and 
inhibition of nucleophosmin, and concomitant increase in drug resistance potential of cancer 
cells. Recent evidence shows that aberrant expression of TG2 in mammary epithelial cells 
confers stem cell characteristics on the cells (Kumar et al. 2011). Similarly, Kumar and 
colleagues reported that high basal expression of TG2 in breast cancer cells promotes the 
development of stem cell features, but did not mediate their terminal differentiation (Kumar 
et al. 2011). Additionally, Caffarel et al (2013) observed that the activation of TG2:integrin-
α5ß1 interactions through the stimulation of oncostatin M receptor in cervical squamous cell 
carcinoma induced pro-malignant changes.  
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Clinically, TG2 has been reported to serve as a predictive indicator of anticancer therapeutic 
efficacy. For instance, Jeong et al (2013) suggested that TG2 expression is a promising 
indicator of the effectiveness of epidermal growth factor receptor tyrosine kinase inhibitor 
(EGFR-TKI) therapy in patients suffering from non-small cell lung cancer. Similarly, Assi et 
al. (2013) reported that the accumulation of TG2 in tumour stroma can serve as an 
independent risk factor for the identification of invasive ductal carcinomas (IDCs) of breast, 
and can establish breast cancer patients at high risk of recurrence. They also observed that 
overexpression of TG2 can serve as an indicator of poor prognosis for IDC of the breast. 
Agnihotri et al. (2013) proposed that inflammation-induced progression of breast cancer and 
acquisition of survival and invasive capabilities by breast cancer cells are mediated by TG2. 
In acute myeloid leukaemia, Pierce et al (2013) demonstrated that increased expression of 
TG2 precipitated a more advanced state of the disease in relapse patients. They further 
established that increased TG2 expression correlates with the expression of proteins involved 
in apoptosis, motility and extracellular matrix association; processes that have been linked 
with leukemia development and progression. This is a testament to the specialized ability of 
TG2 to interact with several proteins as substrates in various biological events, probably due 
to the unique biochemical structure of TG2 that is uncharacteristic of other transglutaminase 
enzymes. 
 
5.0: Compensation for transglutaminase 2 functions 
Regardless of the wide range of biological functionalities associated with TG2, and amidst its 
unique cellular biochemistry, its exact physiological functions are still debated. This debate is 
complicated by the fact that homozygous deletion of TG2 in mice does not result in an 
embryonic lethal phenotype (De Laurenzi et al. 2001; Nanda et al. 2001), suggesting that 
compensation for its absence may be achieved by other family members. Such knockouts are 
not however without associated pathology. For example, Bernassola et al (2002) observed 
that TG2-deficient mice displayed significant changes such as characteristic glucose 
intolerance and hyperglycaemia due to reduced insulin secretion, a condition equivalent to a 
subtype of diabetes called maturity-onset diabetes of the young (MODY). Moreover, a TG2-
deficiency disease is yet to be identified in humans implying the importance of its presence. 
This notion is further supported by the observation that TG2 is relatively more abundant than 
other members of the transglutaminase family. Its wide tissue distribution and its possession 
of a wide range of structural features that allows for flexibility in interaction with widely 
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assorted proteins are some of the factors that give TG2 a potentially wide range of functions 
other than simple enzymatic activity.   
Thus while there are increasing suggestions of possible compensation for the absence of TG2 
by other members of the transglutaminase family (Bernassola et al 2002), the pleiotropic 
nature of this protein indicates that TG2 is actually involved in more physiological processes 
than any other member of the enzyme family and, thus, while TG2 might feasibly 
compensate for other members of the family the suggestion that alternative TG isoforms may 
act as a universal“back up” system for TG2 seems less likely.  
From the above, it seems more appropriate to argue that compensation for TG2’s functions 
by other Tgase isoforms might not be possible, except for roles that are determined by its 
calcium-dependent cross-linking and transamidating activities, which are common features of 
the transglutaminase family. For example, TG2-mediated functions that are enzymatic but 
independent of calcium, such as  its role as a G-protein, protein disulphide isomerase activity, 
kinase function and regulation of energy metabolism, are unlikely roles to be undertaken by 
any other member of the transglutaminase family. This could be due to absence of 
appropriate structural conformation in other transglutaminase enzymes that could enable 
them to alternately assume such roles in the event of TG2 absence.  
 
Similarly, TG2-mediated integrin-fibronectin interaction is critical to many physiological 
events in the cell, including cell adhesion, growth, migration, differentiation, programmed 
cell death, and ECM assembly (Zemskov et al. 2006; Belkin 2011). Such interaction is vital 
to many cellular processes and serves as one of the major routes for extracellular survival, 
signalling activation and consequent apoptotic evasion. It is non-enzymatic and independent 
of TG2 transamidation and cross-linking activities. Consequently, it is unlikely that any other 
member of the transglutaminase family can successfully compensate for this function in the 
event of TG2 absence.  
 
6.0: Conclusions  
The abundance of TG2 in various cell types, its specialized structural conformation, and its 
broad substrate specificity are some of the key factors justifying the enzyme’s implication in 
myriads of biological events. From this review, it is evident that beside its calcium-dependent 
activities, TG2 can enzymatically or non-enzymatically mediate key cell physiological 
events. However, it has been increasingly suggested that in the event of TG2 absence its 
biological functions could be successfully compensated for by other members of the 
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transglutaminase family. These suggestions have been made without recourse to the 
distinguishing features of TG2 among the transglutaminase family. It is necessary to carry out 
further investigations to ascertain the main reasons why TG2 knockout is not embryonic 
lethal, instead of relying on the assertion that its functions are compensated for by other 
transglutaminase enzymes. Finally, it is also our view that a systematic investigation should 
be carried out to establish with certainty, the possibility of and premise for the replacement of 
TG2 function by any other member of the transglutaminase family.  
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